Cargando…

Research progress and design optimization of CAR‐T therapy for pancreatic ductal adenocarcinoma

Pancreatic ductal adenocarcinoma (PDAC) is a highly malignant cancer with limited treatment options. Chimeric antigen receptor T cells (CAR‐T) are genetically engineered T cells that can specifically kill tumor cells without major histocompatibility complex restriction. Encouraging progress in CAR‐T...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Tianjiao, Li, Hao, Li, Shuo, Xu, Shuaishuai, Zhang, Wuhu, Gao, Heli, Xu, Huaxiang, Wu, Chuntao, Wang, Wenquan, Yu, Xianjun, Liu, Liang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Cancer Biology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6718528/ https://www.ncbi.nlm.nih.gov/pubmed/31339230 http://dx.doi.org/10.1002/cam4.2430

Ejemplares similares

Prognostic value of γ‐glutamyltransferase‐to‐albumin ratio in patients with pancreatic ductal adenocarcinoma following radical surgery
por: Li, Shuo, et al.
Publicado: (2019)

The systemic inflammation response index predicts survival and recurrence in patients with resectable pancreatic ductal adenocarcinoma
por: Li, Shuo, et al.
Publicado: (2019)

The role of collagen in cancer: from bench to bedside
por: Xu, Shuaishuai, et al.
Publicado: (2019)

Dissecting cell-type-specific metabolism in pancreatic ductal adenocarcinoma
por: Lau, Allison N, et al.
Publicado: (2020)

Follicular Helper T Cells Remodel the Immune Microenvironment of Pancreatic Cancer via Secreting CXCL13 and IL-21
por: Lin, Xuan, et al.
Publicado: (2021)

Spatial determination and prognostic impact of the fibroblast transcriptome in pancreatic ductal adenocarcinoma
por: Croft, Wayne, et al.
Publicado: (2023)

Hypoxia-reprogrammed regulatory group 2 innate lymphoid cells promote immunosuppression in pancreatic cancer
por: Ye, Longyun, et al.
Publicado: (2022)

Analysis of distinct long noncoding RNA transcriptional fingerprints in pancreatic ductal adenocarcinoma
por: Yu, Xiang, et al.
Publicado: (2017)

Mechanisms of drug resistance of pancreatic ductal adenocarcinoma at different levels
por: Du, Jiali, et al.
Publicado: (2020)

The limits of molecular signatures for pancreatic ductal adenocarcinoma subtyping
por: Lautizi, Manuela, et al.
Publicado: (2022)

Expression of SNAIL in accompanying PanIN is a key prognostic indicator in pancreatic ductal adenocarcinomas
por: Fujiwara, Sho, et al.
Publicado: (2019)

Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma
por: Zhang, Aibin, et al.
Publicado: (2017)

Tumor infiltrating neutrophils and gland formation predict overall survival and molecular subgroups in pancreatic ductal adenocarcinoma
por: Naso, Julia R., et al.
Publicado: (2020)

Distal bile duct carcinomas and pancreatic ductal adenocarcinomas: postulating a common tumor entity
por: Schmuck, Rosa B., et al.
Publicado: (2015)

Tumor‐driven like macrophages induced by conditioned media from pancreatic ductal adenocarcinoma promote tumor metastasis via secreting IL‐8
por: Chen, Shao‐jie, et al.
Publicado: (2018)

Neutrophil–lymphocyte ratio (NLR) was associated with prognosis and immunomodulatory in patients with pancreatic ductal adenocarcinoma (PDAC)
por: Xiang, Zi-jun, et al.
Publicado: (2020)

LncRNA LUCAT1 contributes to cell proliferation and migration in human pancreatic ductal adenocarcinoma via sponging miR‐539
por: Nai, Yongjun, et al.
Publicado: (2019)

Targeting claudin‐4 enhances chemosensitivity of pancreatic ductal carcinomas
por: Sasaki, Takamitsu, et al.
Publicado: (2019)

GATA4 Regulates Inflammation-Driven Pancreatic Ductal Adenocarcinoma Progression
por: Jiang, Weiliang, et al.
Publicado: (2021)

Precise and efficient silencing of mutant Kras(G12D) by CRISPR-CasRx controls pancreatic cancer progression
por: Jiang, Wang, et al.
Publicado: (2020)

KRAS mutation: The booster of pancreatic ductal adenocarcinoma transformation and progression
por: Zhang, Zining, et al.
Publicado: (2023)

Possible Molecular Markers for the Diagnosis of Pancreatic Ductal Adenocarcinoma
por: Shen, Quan, et al.
Publicado: (2018)

A feasible CT feature to differentiate focal‐type autoimmune pancreatitis from pancreatic ductal adenocarcinoma
por: He, Chaobin, et al.
Publicado: (2019)

The clinical relevance of the Hippo pathway in pancreatic ductal adenocarcinoma
por: Drexler, Richard, et al.
Publicado: (2020)

Switchable CAR-T cells mediate remission in metastatic pancreatic ductal adenocarcinoma
por: Raj, Deepak, et al.
Publicado: (2019)

Retraction: GATA4 regulates inflammation-driven pancreatic ductal adenocarcinoma progression
Publicado: (2023)

SCF, Regulated by HIF-1α, Promotes Pancreatic Ductal Adenocarcinoma Cell Progression
por: Gao, Chuntao, et al.
Publicado: (2015)

Burden of hereditary cancer susceptibility in unselected patients with pancreatic ductal adenocarcinoma referred for germline screening
por: Cremin, Carol, et al.
Publicado: (2020)

Impact of the COVID-19 Pandemic on Management of Patients with Metastatic Pancreatic Ductal Adenocarcinoma in the United States
por: Paluri, Ravi, et al.
Publicado: (2022)

Differentiation of atypical pancreatic neuroendocrine tumors from pancreatic ductal adenocarcinomas: Using whole‐tumor CT texture analysis as quantitative biomarkers
por: Li, Jiali, et al.
Publicado: (2018)

Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
por: Bijlsma, Maarten F., et al.
Publicado: (2022)

Elevated glypican‐1 expression is associated with an unfavorable prognosis in pancreatic ductal adenocarcinoma
por: Lu, Haizhen, et al.
Publicado: (2017)

Modified gemcitabine plus nab‐paclitaxel regimen in advanced pancreatic ductal adenocarcinoma
por: Rogers, Jane E., et al.
Publicado: (2020)

Syk Inhibition Reprograms Tumor-Associated Macrophages and Overcomes Gemcitabine-Induced Immunosuppression in Pancreatic Ductal Adenocarcinoma
por: Rohila, Deepak, et al.
Publicado: (2023)

PHD finger protein 5A promoted lung adenocarcinoma progression via alternative splicing
por: Mao, Shuangshuang, et al.
Publicado: (2019)

Aberrant DNA methyltransferase expression in pancreatic ductal adenocarcinoma development and progression
por: Gao, Jun, et al.
Publicado: (2013)

Hyperdense Pancreatic Ductal Adenocarcinoma: Clinical Characteristics and Proteomic Landscape
por: Xu, He, et al.
Publicado: (2021)

Development and validation of novel nomograms for predicting the survival of patients after surgical resection of pancreatic ductal adenocarcinoma
por: Li, Ge, et al.
Publicado: (2020)

Effect of Perioperative CEA and CA24-2 on Prognosis of Early Resectable Pancreatic Ductal Adenocarcinoma
por: Li, Xiaojie, et al.
Publicado: (2020)

Progress in Animal Models of Pancreatic Ductal Adenocarcinoma
por: Kong, Kaiwen, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_s42p5d9135f74cdap0ptrisb25